They can downregulate PD-L1 expression in tumor cells, reduce the activity of immunosuppressive regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), and enhance the efficacy of immune checkpoint inhibitors such as anti–PD-1/PD-L1 antibodies [34]. This evidence concerns the gene PDCD1 and neoplasm.